Faecal immunochemical tests versus guaiac faecal occult blood tests: What clinicians and colorectal cancer screening programme organisers need to know

Gut

Volumn 64, Issue 8, 2015, Pages 1327-1337

  Tinmouth, Jill ^a   Lansdorp Vogelaar, Iris ^b   Allison, James E ^c  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; GUAIAC;

ARTICLE; CANCER MORTALITY; CANCER SCREENING; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FECAL IMMUNOCHEMICAL TEST; FECES ANALYSIS; GASTROINTESTINAL ENDOSCOPY; GUAIAC BASED FECAL OCCULT BLOOD TEST; HEMOGLOBIN DETERMINATION; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOCHEMISTRY; IMMUNOLOGY TEST KIT; INTERMETHOD COMPARISON; OCCULT BLOOD TEST; POINT OF CARE TESTING; PRIORITY JOURNAL; QUALITATIVE DIAGNOSIS; QUANTITATIVE DIAGNOSIS; SENSITIVITY AND SPECIFICITY; SIGMOIDOSCOPY; CHEMISTRY; COLORECTAL NEOPLASMS; DIAGNOSTIC USE; EARLY DIAGNOSIS; FECES; MASS SCREENING; OCCULT BLOOD; PROCEDURES;

COLONOSCOPY; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FECES; GUAIAC; HEMOGLOBINS; HUMANS; INDICATORS AND REAGENTS; MASS SCREENING; OCCULT BLOOD;

EID: 84940463003     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-308074     Document Type: Article

References (94)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010;375:1624-33.
3. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-7.
4. Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348:1467-71.
5. Schoen RE, Pinsky PF, Weissfeld JL, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med 2012;366:2345-57.
6. Segnan N, Armaroli P, Bonelli L, et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian randomized controlled trial-SCORE. J Natl Cancer Inst 2011;103:1310-22.
7. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993;328:1365-71.
8. Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000;343:1603-7.
9. Shaukat A, Mongin SJ, Geisser MS, et al. Long-term mortality after screening for colorectal cancer. N Engl J Med 2013;369:1106-14.
10. UK National Screening Committee. Criteria for appraising the viability, effectiveness and appropriateness of a screening programme. 2009. http://www.screening.nhs.uk/criteria.
11. Raffle AE, Muir Gray JA. Screening: evidence and practice. Oxford University Press, 2007.
12. Boot K. 'Ik doe niet mee aan de darmkankerscreening' ["I do not participate in the colorectal cancer screening]". Netherlands: deVolkskrant, 2014. (updated 20 January 2014). http:/www.volkskrant.nl/dossier-zorg/ik-doe-niet-mee-aan-dedarmkankerscreening~a3580351/.
13. Hairwassers D, Jonkers A. Screening darmkanker biedt valse beloften [Screening cancer offers false promises]. Netherlands: deVerdieping Trouw, 2014. (updated 13 Jan 2014). http://www.trouw.nl/tr/nl/4516/Gezondheid/article/detail/3576471/2014/01/13/Screening-darmkanker-biedt-valse-beloften.dhtml.
14. Levin B, Lieberman D, McFarland B, et al., American Cancer Society Colorectal Cancer Advisory Group; US Multi-Society Task Force; American College of Radiology Colon Cancer Committee. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008;134:1570-95.
15. Wilson JMG, Jungner G. Principles and practice of screening for disease. Geneva: World Health Organization, 1968.
16. Miles A, Cockburn J, Smith RA, et al. A Perspective from countries using organized screening programs. Cancer 2004;104(5 Suppl):1201-13.
17. Schreuders EH, Ruco A, Rabeneck L, et al. Colorectal cancer screening; a global overview of existing programs. Gut Published Online First: 3 June 2015 doi:10.1136/gutjnl-2014-309086.
18. Allison JE, Fraser CG, Halloran SP, et al. Population screening for colorectal cancer means getting FIT: The past, present, and future of colorectal cancer screening using the fecal immunochemical test for hemoglobin (FIT). Gut Liver 2014;8:117-30.
19. European Commission. European guidelines for quality assurance in colorectal cancer screening and diagnosis. Luxembourg: International Agency for Research on Cancer, 2010. http://bookshop.europa.eu/is-bin/INTERSHOP.enfinity/WFS/EU-Bookshop-Site/en-GB/-/EUR/ViewPublication-Start;pgid=y8dIS7GUWMdSR0EAlMEUUsWb00003cwwKX6s;sid=-Xdr61JYrdZr6×8iv9-1TDB9-qRtOB875wU=?PublicationKey=ND3210390.
20. Rabeneck L, Rumble RB, Thompson F, et al. Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening. Can J Gastroenterol 2012;26:131-47.
21. Greegor DH. Diagnosis of large-bowel cancer in the asymptomatic patient. JAMA 1967;201:943-5.
22. Allison JE, Feldman R, Tekawa IS. Hemoccult screening in detecting colorectal neoplasm: sensitivity, specificity, and predictive value. Long-term follow-up in a large group practice setting. Ann Intern Med 1990;112:328-33.
23. Rockey DC. Occult gastrointestinal bleeding. N Engl J Med 1999;341:38-46.
24. Ontario Ministry of Health and Long Term Care. FOBT (Fecal Occult Blood Test) Instructions. 2010. (cited 18 Nov 2014). http://health.gov.on.ca/en/public/programs/coloncancercheck/docs/fobt/English-FOBT-instructions.pdf.
25. Carroll MR, Seaman HE, Halloran SP. Tests and investigations for colorectal cancer screening. Clin Biochem 2014;47:921-39.
26. Lieberman DA, Weiss DG, Veterans Affairs Cooperative Study Group 380. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med 2001;345:555-60.
27. Allison JE, Sakoda LC, Levin TR, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst 2007;99:1462-70.
28. Allison JE, Tekawa IS, Ransom LJ, et al. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996;334:155-9.
29. Levi Z, Birkenfeld S, Vilkin A, et al. A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility study. Int J Cancer 2011;128:2415-24.
30. Hundt S, Haug U, Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med 2009;150:162-9.
31. Levy BT, Bay C, Xu Y, et al. Test characteristics of faecal immunochemical tests (FIT) compared with optical colonoscopy. J Med Screen 2014;21:133-43.
32. Chiang T-H, Chuang S-L, Chen SL-S, et al. Difference in performance of fecal immunochemical tests with the same hemoglobin cut-off concentration in a nationwide colorectal cancer screening program. Gastroenterology 2014;147:1317-26.
33. Catomeris P, Baxter NN, Boss S, et al. Effect of temperature, time and freeze/thaw cycles on the stability of fecal hemoglobin using five commercial fecal immunochemical test (FIT) methods and one guaiac method. Gastroenterology 2014;146:S-404.
34. Guittet L, Bailly L, Bouvier V, et al. Indirect comparison of two quantitative immunochemical faecal occult blood tests in a population with average colorectal cancer risk. J Med Screen 2011;18:76-81.
35. Hewitson P, Glasziou P, Watson E, et al. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 2008;103:1541-9.
36. Zorzi M, Fedeli U, Schievano E, et al. Impact on colorectal cancer mortality of screening programmes based on the faecal immunochemical test. Gut 2015;64:674-90.
37. Fletcher RH. Commentary. ACP J Club 1996;124:74.
38. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
39. Hassan C, Hunink MM, Laghi A, et al. Value-of-information analysis to guide future research in colorectal cancer screening. Radiology 2009;253:745-52.
40. Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, et al. Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population. J Natl Cancer Inst 2010;102:1238-52.
41. Federici A, Giorgi Rossi P, Borgia P, et al. The immunochemical faecal occult blood test leads to higher compliance than the guaiac for colorectal cancer screening programmes: a cluster randomized controlled trial. J Med Screen 2005;12:83-8.
42. Hoffman RM, Steel S, Yee EF, et al. Colorectal cancer screening adherence is higher with fecal immunochemical tests than guaiac-based fecal occult blood tests: a randomized, controlled trial. Prev Med 2010;50:297-9.
43. Hol L, Wilschut JA, van Ballegooijen M, et al. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer 2009;100:1103-10.
44. van Rossum LG, van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008;135:82-90.
45. Cole SR, Young GP, Esterman A, et al. A randomised trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer. J Med Screen 2003;10:117-22.
46. Hassan C, Giorgi Rossi P, Camilloni L, et al. Meta-analysis: adherence to colorectal cancer screening and the detection rate for advanced neoplasia, according to the type of screening test. Aliment Pharmacol Ther 2012;36:929-40.
47. Crotta S, Segnan N, Paganin S, et al. High rate of advanced adenoma detection in 4 rounds of colorectal cancer screening with the fecal immunochemical test. Clin Gastroenterol Hepatol 2012;10:633-8.
48. Digby J, McDonald PJ, Strachan JA, et al. Use of a faecal immunochemical test narrows current gaps in uptake for sex, age and deprivation in a bowel cancer screening programme. J Med Screen 2013;20:80-5.
49. Kapidzic A, Grobbee EJ, Hol L, et al. Attendance and yield over three rounds of population-based fecal immunochemical test screening. Am J Gastroenterol 2014;109:1257-64.
50. Lee JK, Liles EG, Bent S, et al. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med 2014;160:171.
51. Brenner H, Tao S. Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy. Eur J Cancer 2013;49:3049-54.
52. Park DI, Ryu S, Kim YH, et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol 2010;105:2017-25.
53. Parra-Blanco A, Gimeno-Garcia AZ, Quintero E, et al. Diagnostic accuracy of immunochemical versus guaiac faecal occult blood tests for colorectal cancer screening. J Gastroenterol 2010;45:703-12.
54. Graser A, Stieber P, Nagel D, et al. Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population. Gut 2009;58:241-8.
55. van Rossum LG, van Rijn AF, van Munster IP, et al. Earlier stages of colorectal cancer detected with immunochemical faecal occult blood tests. Neth J Med 2009;67:182-6.
56. Fraser CG, Allison JE, Young GP, et al. Quantitation of hemoglobin improves fecal immunochemical tests for noninvasive screening. Clin Gastroenterol Hepatol 2013;11:839-40.
57. Dominitz JA, DJ R. Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM). (cited 19 May 2014). http://clinicaltrials.gov/ct2/show/NCT01239082.
58. Quintero E, Castells A, Bujanda L, et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 2012;366:697-706.
59. Hol L, van Leerdam ME, van Ballegooijen M, et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010;59:62-8.
60. Segnan N, Senore C, Andreoni B, et al. Comparing attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for colorectal cancer screening. Gastroenterology 2007;132:2304-12.
61. Multicentre Australian Colorectal-neoplasia Screening (MACS) Group. A comparison of colorectal neoplasia screening tests: a multicentre community-based study of the impact of consumer choice. Med J Aust 2006;184:546-50.
62. Quintero E, Carrillo M, Gimeno-Garcia AZ, et al. Equivalency of fecal immunochemical tests and colonoscopy in familial colorectal cancer screening. Gastroenterology 2014;147:1021-30.e1; quiz e16-17.
63. Allison JE. Colorectal-cancer screening. N Engl JMed 2012;366:2130; author reply 1231.
64. Allison JE, Meijer GA. Colonic polyps: The harm of overdiagnosis. Pract Gastroenterol 2012:25-38.
65. Lansdorp-Vogelaar I, Knudsen AB, Brenner H. Cost-effectiveness of colorectal cancer screening. Epidemiol Rev 2011;33:88-100.
66. Chen LS, Liao CS, Chang SH, et al. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16). J Med Screen 2007;14:191-9.
67. Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, et al. Stool DNA testing to screen for colorectal cancer in the Medicare population: a cost-effectiveness analysis. Ann Intern Med 2010;153:368-77.
68. Parekh M, Fendrick AM, Ladabaum U. As tests evolve and costs of cancer care rise: reappraising stool-based screening for colorectal neoplasia. Aliment Pharmacol Ther 2008;27:697-712.
69. van Ballegooijen M, Habbema JD, Boer R, et al. A comparison of the cost-effectiveness of fecal occult blood tests with different test characteristics in the context of annual screening in the Medicare population. Rockville, MD, USA: Agency for Healthcare Research and Quality, 2003.
70. Berchi C, Guittet L, Bouvier V, et al. Cost-effectiveness analysis of the optimal threshold of an automated immunochemical test for colorectal cancer screening: performances of immunochemical colorectal cancer screening. Int J Technol Assess Health Care 2010;26:48-53.
71. Lejeune C, Dancourt V, Arveux P, et al. Cost-effectiveness of screening for colorectal cancer in France using a guaiac test versus an immunochemical test. Int J Technol Assess Health Care 2010;26:40-7.
72. Wilschut JA, Hol L, Dekker E, et al. Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening. Gastroenterology 2011;141:1648-55.e1.
73. Wilschut JA, Habbema JD, van Leerdam ME, et al. Fecal occult blood testing when colonoscopy capacity is limited. J Natl Cancer Inst 2011;103:1741-51.
74. Levin B, Lieberman DA, McFarland B, et al, American Cancer Society Colorectal Cancer Advisory Group; US Multi-Society Task Force; American College of Radiology Colon Cancer Committee. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008;58: 130-60.
75. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, et al. Evaluating test strategies for colorectal cancer screening: a decision analysis for the US Preventive Services Task Force. Ann Intern Med 2008;149:659-69.
76. Allison JE, Fraser CG, Halloran SP, et al. Comparing fecal immunochemical tests: improved standardization is needed. Gastroenterology 2012;142:422-4.
77. van Veldhuizen H, Heijnen M-L, Lansdorp-Vogelaar I. Adjustment to the implementation of the colorectal cancer screening programme in 2014 and 2015. Netherlands: National Institute for Public Health and the Environment, Ministry of Health, Welfare and Sport, 2014.
78. Grazzini G, Ventura L, Zappa M, et al. Influence of seasonal variations in ambient temperatures on performance of immunochemical faecal occult blood test for colorectal cancer screening: observational study from the Florence district. Gut 2010;59:1511-15.
79. Auge JM, Pellise M, Escudero JM et al. Risk Stratification for Advanced Colorectal Neoplasia According to Fecal Hemoglobin Concentration in a Colorectal Cancer Screening Program. Gastroenterology 2014;147:628-636.
80. Stegeman I, de Wijkerslooth TR, Stoop EM, et al. Combining risk factors with faecal immunochemical test outcome for selecting CRC screenees for colonoscopy. Gut 2014;63:466-71.
81. Grazzini G, Visioli CB, Zorzi M, et al. Immunochemical faecal occult blood test: number of samples and positivity cutoff. What is the best strategy for colorectal cancer screening? Br J Cancer 2009;100:259-65.
82. Guittet L, Guillaume E, Levillain R, et al. Analytical comparison of three quantitative immunochemical fecal occult blood tests for colorectal cancer screening. Cancer Epidemiol Biomarkers Prev 2011;20:1492-501.
83. van Roon AH, Wilschut JA, Hol L, et al. Diagnostic yield improves with collection of 2 samples in fecal immunochemical test screening without affecting attendance. Clin Gastroenterol Hepatol 2011;9:333-9.
84. Goede SL, van Roon AH, Reijerink JC, et al. Cost-effectiveness of one versus two sample faecal immunochemical testing for colorectal cancer screening. Gut 2013;62:727-34.
85. van Roon AH, Hol L, van Vuuren AJ, et al. Are fecal immunochemical test characteristics influenced by sample return time? A population-based colorectal cancer screening trial. Am J Gastroenterol 2012;107:99-107.
86. Randell E, Kennell M, Taher A, et al. Evaluation of Hemo Techt NS-Plus system for use in a province-wide colorectal cancer screening program. Clin Biochem 2013;46:365-8.
87. Vilkin A, Rozen P, Levi Z, et al. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol 2005;100:2519-25.
88. Australian Institute of Health and Welfare. National Bowel Cancer Screening Program monitoring report: phase 2, July 2008-June 2011. Cancer Series No. 65, CAN 61. Canberra: Australian Institute of Health and Welfare, 2012.
89. Carroll MRR, Piggott C, Pearson S, et al. Evaluation of quantitative fecal immunochemical tests for haemoglobin. Guildford, United Kingdom: Guildford Medical Device Evaluation Centre, 2013.
90. Lampf SA, Binnett WE, Brannon CR, et al. Evaluation report: immunochemical faecal occult blood tests. United Kingdom: National Health Service: Purchasing and Supply Agency, 2009.
91. Potter MB, Ackerson LM, Gomez V, et al. Effectiveness and reach of the FLU-FIT program in an integrated health care system: a multisite randomized trial. Am J Public Health 2013;103:1128-33.
92. Potter MB, Gildengorin G, Wang Y, et al. Comparative effectiveness of two pharmacy-based colorectal cancer screening interventions during an annual influenza vaccination campaign. J Am Pharm Assoc (2003) 2010;50:181-7.
93. Potter MB, Phengrasamy L, Hudes ES, et al. Offering annual fecal occult blood tests at annual flu shot clinics increases colorectal cancer screening rates. Ann Fam Med 2009;7:17-23.
94. Potter MB, Somkin CP, Ackerson LM, et al. The FLU-FIT program: an effective colorectal cancer screening program for high volume flu shot clinics. Am J Manag Care 2011;17:577-83.